Preetpal Singh is Group Managing Director at Xebia, where he leads global initiatives focused on building and modernizing digital platforms, enterprise applications, and data-driven systems. With more ...

Expert insights into CDD Vault's data management system explain how the platform uses the latest technology to support ...

Enterprise technology vendors are racing to make AI work against the structured and relational data inside databases, data ...

Pichai's "agent manager" quote made headlines. The rest of the interview reveals a timeline, infrastructure constraints, and ...

Nvidia has a structured data enablement strategy. Nvidia provides libaries, software and hardware to index and search data faster. The Indexing and retrievals are way faster 10-40X faster in most ...

WASHINGTON — President Donald Trump indicated Thursday that he wants to see Iran's leadership structure fully removed and that he has some names in mind for a "good leader." Subscribe to read this ...

Hyperscale data centers raise concerns among Wisconsin residents about water and energy consumption. Most of a data center's water usage comes from generating the massive amount of electricity ...

The windowless buildings rising across North Carolina look more like warehouses than engines of climate change. They have no smokestacks and no obvious emissions. But inside, thousands of servers run ...

CLEVELAND, Ohio – Ohio ranks fifth in the nation when it comes to the number of data centers being constructed to power the rise of artificial intelligence and other computer services. They have been ...

ABSTRACT: Objective: The purpose of this study was to elucidate clinical factors influencing quality of life (QOL) in anorexia nervosa (AN) patients. Methods: Twenty female patients with AN (median ...

Structure Therapeutics’ stock soared toward an 18-month high in early Monday trading, after mid-stage data for its oral daily GLP-1 receptor appeared comparable to that of one of Eli Lilly’s ...

Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...